Updated: 27 March 2023
Our research program is inspired by the practices of the pharmaceutical industry and includes research on product development, methods to substantiate risk reduction and ways to assess the impact on population harm. We believe it is important to share our data to facilitate and encourage independent verification of methodologies and findings.
PMI accepts proposals under an Investigator Initiated Studies program, to support external scientists to advance and verify RRP science. Check the list of supported studies.
Those interested in submitting a proposal to the program should first read the guidelines and the terms and conditions of the program. Then they can download the IIS concept proposal submission template for the first step of the application process, and email their submissions to iis.pmi@pmi.com.
The IIS program currently focuses on clinical studies in countries where PMI’s commercialized RRPs are already available on the market. The program's scope also includes aerosol chemistry, toxicology, systems biology, and post-market surveillance studies. This corresponds to our scientific assessment built on a collaborative approach and expertise in the fields of physics, chemistry, biology, informatics, and medicine.
Through efforts like the IIS program, PMI has scientifically collaborated with more than 20 researchers worldwide, generating the same number of scientific publications. We continue to accept applications to support clinical interventional and observational studies, real-world evidence, toxicology studies of PMI’s commercialized smoke-free products, and others. Learn more about IIS supported studies.
